Design
Review
Authors
Loading...
Should not yet change metabolic risk assessment; leaves open prospective validation of omentin as a biomarker.
Key points are not available for this paper at this time.
Hałabiś et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: